Phase II and pharmacogenomics study of enzastaurin plus temozolomide during and following radiation therapy in patients with newly diagnosed glioblastoma multiforme and gliosarcoma

This open-label, single-arm, phase II study combined enzastaurin with temozolomide plus radiation therapy (RT) to treat glioblastoma multiforme (GBM) and gliosarcoma. Adults with newly diagnosed disease and Karnofsky performance status (KPS) ≥ 60 were enrolled. Treatment was started within 5 weeks a...

Description complète

Enregistré dans:
Détails bibliographiques
Auteurs principaux: Butowski, Nicholas, Chang, Susan M., Lamborn, Kathleen R., Polley, Mei–Yin, Pieper, Russell, Costello, Joseph F., Vandenberg, Scott, Parvataneni, Rupa, Nicole, Angelina, Sneed, Patricia K., Clarke, Jennifer, Hsieh, Emily, Costa, Bruno M., Reis, Rui M., Hristova-Kazmierski, Maria, Nicol, Steven J., Thornton, Donald E., Prados, Michael D.
Format: Artigo
Langue:Inglês
Publié: Oxford University Press 2011
Sujets:
Clinical Investigations
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC3223090/
https://ncbi.nlm.nih.gov/pubmed/21896554
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/nor130
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires